Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study
- None.
- None.
The announcement of a $20M milestone payment from Janssen to NANOBIOTIX is a significant financial event for the company. As a late-clinical stage biotechnology firm, such inflows are crucial for funding ongoing research and development activities. This payment likely reflects the achievement of predefined operational objectives in the NANORAY-312 Phase 3 study, which is a common practice in strategic partnerships within the biotech industry. The financial health of NANOBIOTIX could be positively impacted in the short-term, as this capital infusion enhances their cash reserves, potentially extending their operational runway and reducing immediate dilution risk for existing shareholders.
Long-term implications hinge on the successful development and potential market approval of NBTXR3. If proven effective and safe, NBTXR3 could capture a significant share of the head and neck cancer treatment market, especially among elderly patients. As a first-in-class radioenhancer, it represents a novel approach in oncology, potentially leading to improved patient outcomes and creating a new standard of care. However, investors should consider the inherent risks of clinical trials, regulatory hurdles and market adoption, which could affect the long-term return on investment.
The progression of the NANORAY-312 pivotal Phase 3 study is a critical step for NANOBIOTIX, as it brings the company closer to potential registration and commercialization of NBTXR3. The study focuses on a radioenhancer designed to improve the efficacy of radiotherapy, a common treatment for head and neck cancer. Elderly patients often have limited treatment options due to the increased risk of adverse effects from conventional therapies, making the development of NBTXR3 particularly impactful for this demographic.
From a medical research perspective, the success of NBTXR3 could represent a paradigm shift in cancer treatment, emphasizing the importance of physics-based approaches alongside traditional chemical and biological methods. The milestone payment from Janssen not only validates the operational progress of the study but also demonstrates confidence in the potential of the treatment. It is imperative to monitor further clinical results for efficacy and safety data, as these will be pivotal in determining the drug's viability and impact on patient care.
The strategic partnership between NANOBIOTIX and Janssen, evidenced by the milestone payment, suggests a strong commercial interest in NBTXR3. The head and neck cancer market is witnessing a growing demand for innovative treatments that can be effective in the elderly population, which is often underrepresented in clinical trials. If NBTXR3 is successful, it could meet a significant unmet medical need and command premium pricing, potentially disrupting the market.
Market analysts will be keen to assess the size of the addressable market for NBTXR3, the competitive landscape and the potential market share that NANOBIOTIX could capture with its radioenhancer. The partnership with Janssen, a well-established pharmaceutical company, could provide strategic advantages in terms of marketing, distribution and navigating the complex regulatory environment. The impact on NANOBIOTIX's stock will likely be correlated with the market's perception of the drug's future success, influenced by ongoing trial results and competitive developments.
PARIS and CAMBRIDGE, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced achievement of operational requirements in NANORAY-312, an ongoing pivotal Phase 3 study evaluating potential first-in-class radioenhancer NBTXR3 for elderly patients with head and neck cancer, resulting in a
“This first milestone payment related to our ongoing pivotal Phase 3 study evaluating NBTXR3 for patients with head and neck cancer represents another step forward in our pathway to bring NBTXR3 to registration,” said Laurent Levy, Nanobiotix co-founder and chairman of the executive board. “We look forward to continued collaboration with Janssen as we work to deliver the potential benefits of NBTXR3 to millions of patients around the world.”
This
About NBTXR3
NBTXR3 is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles that is administered via one-time intratumoral injection and activated by radiotherapy. Its proof-of-concept was achieved in soft tissue sarcomas for which the product received a European CE mark in 2019. The product candidate’s physical mechanism of action (MoA) is designed to induce significant tumor cell death in the injected tumor when activated by radiotherapy, subsequently triggering adaptive immune response and long-term anti-cancer memory. Given the physical MoA, Nanobiotix believes that NBTXR3 could be scalable across any solid tumor that can be treated with radiotherapy and across any therapeutic combination, particularly immune checkpoint inhibitors.
Radiotherapy-activated NBTXR3 is being evaluated across multiple solid tumor indications as a single agent or in combination with anti-PD-1 immune checkpoint inhibitors, including in NANORAY-312—a global, randomized phase III study in locally advanced head and neck squamous cell cancers. In February 2020, the United States Food and Drug Administration granted regulatory Fast Track designation for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, for the treatment of patients with locally advanced HNSCC who are not eligible for platinum-based chemotherapy—the same population being evaluated in the phase III study.
Given the Company’s focus areas, and balanced against the scalable potential of NBTXR3, Nanobiotix has engaged in a collaboration strategy to expand development of the product candidate in parallel with its priority development pathways. Pursuant to this strategy, in 2019 Nanobiotix entered into a broad, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center to sponsor several phase I and phase II studies evaluating NBTXR3 across tumor types and therapeutic combinations. In 2023 Nanobiotix announced a license agreement for the global co-development and commercialization of NBTXR3 with Janssen Pharmaceutica NV.
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France. The company also has subsidiaries in Cambridge, Massachusetts (United States), France, Spain, and Germany. Nanobiotix has been listed on Euronext: Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020.
Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system. The company's resources are primarily devoted to the development of its lead product candidate–NBTXR3—which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for the treatment of patients with soft tissue sarcoma under the brand name Hensify®.
For more information about Nanobiotix, visit us at http://www.nanobiotix.com/ or follow us on LinkedIn and Twitter
Disclaimer
This press release contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the use of proceed therefrom, and the period of time through which the Company’s anticipates its financial resources will be adequate to support operations. Words such as “expects”, “intends”, “can”, “could”, “may”, “might”, “plan”, “potential”, “should” and “will” or the negative of these and similar expressions are intended to identify forward-looking statements. These forward-looking statements, which are based on our management’s current expectations and assumptions and on information currently available to management. These forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those implied by the forward-looking statements, including risks related to Nanobiotix’s business and financial performance, which include the risk that assumptions underlying the Company’s cash runway projections are not realized. Further information on the risk factors that may affect company business and financial performance is included in Nanobiotix’s Annual Report on Form 20-F filed with the SEC on April 24, 2023 under “Item 3.D. Risk Factors”, in Nanobiotix’s 2022 universal registration document filed with the AMF on April 24, 2023 as updated by its first amendment filed with the AMF on November 1st, 2023 and its second amendment filed with the AMF on November 3rd, 2023, in Nanobiotix’s half-year report, which was filed with the SEC on Form 6-K and with the AMF on September 26, 2023, and subsequent filings Nanobiotix makes with the SEC from time to time which are available on the SEC’s website at www.sec.gov. The forward-looking statements included in this press release speak only as of the date of this press release, and except as required by law, Nanobiotix assumes no obligation to update these forward-looking statements publicly.
Contacts
| Nanobiotix | |
Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com | Investor Relations Department Craig West SVP, Investor Relations +1 (617) 583-0211 investors@nanobiotix.com |
| Media Relations | |
FR – Ulysse Communication Pierre-Louis Germain + 33 (0) 6 64 79 97 51 plgermain@ulysse-communication.com | Global – LifeSci Advisors Kevin Gardner +1 (617) 283-2856 kgardner@lifesciadvisors.com |
Attachment
FAQ
What is the name of the biotechnology company mentioned in the press release?
What is the ticker symbol for Nanobiotix?
What is the name of the ongoing pivotal Phase 3 study mentioned in the press release?
What is the potential first-in-class radioenhancer being evaluated in the study?
Who is the strategic partner mentioned in the press release?
